Andere talen IRLAB Therapeutics AB

Aandelen

IRLAB A

SE0012675361

Beurs gesloten - Nasdaq Stockholm Andere beurzen 17:29:46 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,05 ^SEK	+13,48%		+17,04%	+74,00%

08/05	Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
07/05	IRLAB Therapeutics AB en McQuade Center for Strategic Research and Development, LLC gaan een ontwikkelingssamenwerking aan voor IRL757 als nieuwe behandeling voor apathie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IRLAB publishes interim report for the period January-March 2024	08/05
IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	07/05
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy	07/05
IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757	06/05
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757	06/05
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast	06/05
IRLAB publishes Annual Report for 2023	29/04
IRLAB to present at Redeye Investor Forum	16/04
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	25/03
IRLAB Therapeutics Receives Minutes from End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program for Mesdopetam	22/03
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	22/03
IRLAB Therapeutics AB Mesdopetam Displays Antipsychotic Properties in an Advanced Model of Parkinson's Disease Psychosis	19/03
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	19/03
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	19/03
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	29/02
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	28/02
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	27/02
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	22/02
IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam	22/02
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	07/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IRLAB Therapeutics AB

Aandelen

IRLAB A

SE0012675361

Andere talen

Filters